Literature DB >> 12836860

Use of lipid-lowering agents (statins) during pregnancy.

Akiko Hosokawa1, Benjamin Bar-Oz, Shinya Ito.   

Abstract

QUESTION: A 34-year-old patient of mine is taking a 'statin' for hyperlipidemia. She is planning pregnancy and is worried about the safety of the drug. How should I advise her? ANSWER: Limited evidence from animal and human studies indicates that statins should not be taken during pregnancy. If a patient is inadvertently exposed during pregnancy, however, termination does not appear to be medically indicated.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12836860      PMCID： PMC2214243     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  13 in total

Review 1.  Statins: effective antiatherosclerotic therapy.

Authors:  R S Blumenthal
Journal:  Am Heart J       Date:  2000-04       Impact factor: 4.749

2.  Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy.

Authors:  J M Manson; C Freyssinges; M B Ducrocq; W P Stephenson
Journal:  Reprod Toxicol       Date:  1996 Nov-Dec       Impact factor: 3.143

3.  Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits.

Authors:  W Palinski; F P D'Armiento; J L Witztum; F de Nigris; F Casanada; M Condorelli; M Silvestre; C Napoli
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

4.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.

Authors:  C Napoli; F P D'Armiento; F P Mancini; A Postiglione; J L Witztum; G Palumbo; W Palinski
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

5.  Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses.

Authors:  C Napoli; J L Witztum; F Calara; F de Nigris; W Palinski
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.

Authors:  J W Henck; W R Craft; A Black; J Colgin; J A Anderson
Journal:  Toxicol Sci       Date:  1998-01       Impact factor: 4.849

8.  Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation.

Authors:  R V Hrab; H A Hartman; R H Cox
Journal:  Teratology       Date:  1994-07

9.  Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.

Authors:  L A Dostal; J L Schardein; J A Anderson
Journal:  Teratology       Date:  1994-12

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  7 in total

Review 1.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

Review 2.  Acute myocardial infarction in the obstetric patient.

Authors:  Tabassum Firoz; Laura A Magee
Journal:  Obstet Med       Date:  2012-03-22

3.  Transplacental transfer and distribution of pravastatin.

Authors:  Tatiana N Nanovskaya; Svetlana L Patrikeeva; Jonathan Paul; Maged M Costantine; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Am J Obstet Gynecol       Date:  2013-10       Impact factor: 8.661

4.  Simvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat.

Authors:  Brandiese E J Beverly; Christy S Lambright; Johnathan R Furr; Hunter Sampson; Vickie S Wilson; Barry S McIntyre; Paul M D Foster; Gregory Travlos; L Earl Gray
Journal:  Toxicol Sci       Date:  2014-07-23       Impact factor: 4.849

Review 5.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

6.  Gestational hyperlipidemia and acute pancreatitis with underlying partial lipoprotein lipase deficiency and apolipoprotein E3/E2 genotype.

Authors:  Dong Hee Han; In Ho Moh; Doo-Man Kim; Sung Hee Ihm; Moon-Gi Choi; Hyung Joon Yoo; Eun-Gyoung Hong
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

7.  Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models.

Authors:  Jing Huai; Zi Yang; Yan-Hong Yi; Guang-Jiao Wang
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.